Lotrisone: Dual-Action Relief for Fungal and Inflammatory Skin Conditions
Lotrisone
| Product dosage: 10 gr | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 5 | $8.20 | $41.00 (0%) | 🛒 Add to cart |
| 6 | $7.50 | $49.20 $45.00 (9%) | 🛒 Add to cart |
| 7 | $7.00 | $57.40 $49.00 (15%) | 🛒 Add to cart |
| 8 | $6.62 | $65.60 $53.00 (19%) | 🛒 Add to cart |
| 9 | $6.33 | $73.80 $57.00 (23%) | 🛒 Add to cart |
| 10 | $6.10
Best per tube | $82.00 $61.00 (26%) | 🛒 Add to cart |
| Product dosage: 20 gr | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 2 | $21.00 | $42.00 (0%) | 🛒 Add to cart |
| 4 | $18.25 | $84.00 $73.00 (13%) | 🛒 Add to cart |
| 8 | $16.62 | $168.00 $133.00 (21%) | 🛒 Add to cart |
| 16 | $15.88
Best per tube | $336.00 $254.00 (24%) | 🛒 Add to cart |
Synonyms | |||
Lotrisone is a prescription topical medication combining two potent active ingredients—clotrimazole, a broad-spectrum antifungal agent, and betamethasone dipropionate, a high-potency corticosteroid. This synergistic formulation is specifically designed to treat fungal skin infections complicated by inflammation, offering comprehensive therapeutic action against both the underlying infection and its symptomatic manifestations. It is indicated for conditions such as tinea pedis (athlete’s foot), tinea cruris (jock itch), and tinea corporis (ringworm) where significant erythema, pruritus, and scaling are present. By addressing both the pathogen and the inflammatory response, Lotrisone provides rapid symptomatic relief while effectively eradicating the causative fungi, making it a cornerstone in dermatological practice for severe or resistant dermatophytoses.
Features
- Contains 1% clotrimazole and 0.05% betamethasone dipropionate in a optimized cream or lotion base
- Dual-mechanism action: antifungal and anti-inflammatory
- Formulated for enhanced cutaneous penetration and patient compliance
- Available in 15g, 30g, and 45g tubes for tailored treatment duration
- Clinically proven efficacy against dermatophytes, yeasts, and mold-like fungi
- Stabilized emulsion base to minimize separation and ensure consistent dosing
Benefits
- Rapidly reduces itching, redness, swelling, and discomfort associated with inflamed fungal infections
- Eradicates a broad spectrum of causative fungi, preventing recurrence when used as directed
- Convenient twice-daily application supports adherence to treatment regimens
- Minimizes risk of secondary bacterial infections by controlling inflammation and breakdown of skin integrity
- Provides comprehensive management of both infectious and inflammatory components in a single product
- Suitable for intertriginous areas due to its non-greasy, absorbable formulation
Common use
Lotrisone is primarily prescribed for the treatment of cutaneous fungal infections where inflammation is a significant component. Its most frequent applications include tinea pedis (particularly the interdigital and moccasin types), tinea cruris, and tinea corporis that present with pronounced erythema, scaling, and pruritus. It is also used off-label for severe cases of candidal intertrigo and inflammatory forms of pityriasis versicolor. The medication is intended for short-term use (generally up to 2 weeks for tinea cruris/corporis and 4 weeks for tinea pedis) to minimize the risk of corticosteroid-related adverse effects. It should not be used for purely inflammatory conditions without fungal involvement or for prophylaxis.
Dosage and direction
Apply a thin layer of Lotrisone cream or lotion to the affected area twice daily, in the morning and evening. Gently massage until absorbed. Wash hands before and after application unless treating hands. The treatment area should be cleansed and thoroughly dried prior to application. For intertriginous areas (e.g., groin, axillae), apply sparingly to avoid excessive moisture retention. Duration of therapy should not exceed 2 weeks for tinea cruris/corporis or 4 weeks for tinea pedis unless specifically directed by a physician. Do not use occlusive dressings unless explicitly instructed, as this increases systemic absorption and side effect risk. Discontinue use if symptoms resolve earlier than anticipated.
Precautions
Use Lotrisone only as prescribed; prolonged use may lead to skin atrophy, striae, telangiectasia, and hypothalamic-pituitary-adrenal (HPA) axis suppression. Avoid application to the face, groin, or axillae unless directed, due to higher absorption rates in these areas. Do not use in children under 12 years unless under specialist supervision. Monitor for signs of secondary infection; discontinue use if bacterial or viral infection develops. Patients should avoid contact with eyes and mucous membranes. Use with caution in patients with liver impairment, as clotrimazole is metabolized hepatically. Pregnancy Category C: use only if potential benefit justifies potential risk.
Contraindications
Lotrisone is contraindicated in patients with known hypersensitivity to clotrimazole, betamethasone, other imidazoles, or corticosteroids. It should not be used for cutaneous viral infections (e.g., herpes simplex, varicella), untreated bacterial or fungal infections not susceptible to imidazoles, tuberculous or syphilitic skin lesions, or perioral dermatitis. Contraindicated in patients with circulatory compromise or skin ulcers. Should not be applied to rosacea or acne vulgaris. Not for ophthalmic, oral, or intravaginal use.
Possible side effect
Common local reactions include burning, itching, irritation, dryness, erythema, and folliculitis. Less frequently, users may experience skin atrophy, hypopigmentation, hypertrichosis, allergic contact dermatitis, or miliaria. With prolonged use or over large areas, systemic effects may occur, including HPA axis suppression (manifesting as hyperglycemia, glucosuria, Cushing’s syndrome), intracranial hypertension, and growth retardation in children. Secondary infections with bacteria or Candida may develop. Discontinue and consult a physician if severe irritation, blistering, or signs of systemic absorption occur.
Drug interaction
No clinically significant pharmacokinetic interactions have been documented; however, concomitant use with other topical corticosteroids may increase systemic absorption and adverse effects. Use with other hepatically metabolized drugs may theoretically alter clotrimazole clearance, though topical administration minimizes this risk. Caution is advised when using with other agents that suppress the immune system.
Missed dose
Apply the missed dose as soon as remembered, unless it is nearly time for the next scheduled application. Do not double the dose to catch up. Resume the regular dosing schedule. Consistent application is important for efficacy, but occasional missed doses are unlikely to significantly impact treatment outcomes.
Overdose
Topical overdose is unlikely to cause acute systemic toxicity but may result in severe local reactions including intensified skin irritation, erythema, or peeling. Chronic overuse (prolonged application over large areas) may lead to systemic corticosteroid effects such as adrenal suppression, hyperglycemia, or hypertension. Treatment is supportive: discontinue Lotrisone, monitor for HPA axis suppression if symptomatic, and provide symptomatic care for skin reactions. There is no specific antidote.
Storage
Store at controlled room temperature (20–25°C or 68–77°F). Do not freeze. Keep tube tightly closed when not in use. Protect from light and excessive heat. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Discard any product that has changed color, consistency, or odor.
Disclaimer
This information is for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before using any prescription medication. Do not disregard or delay seeking medical advice based on content herein. Individual patient responses may vary. The manufacturer and publisher are not liable for any adverse effects resulting from the use or misuse of this information.
Reviews
Clinical studies demonstrate Lotrisone’s superiority over clotrimazole monotherapy in resolving inflammation and pruritus within the first week of treatment. In a randomized double-blind trial involving participants with tinea cruris, 89% of Lotrisone-treated patients achieved mycological cure by week 2, compared to 72% with clotrimazole alone. Patient-reported outcomes consistently note rapid relief of itching and improved sleep quality. Dermatologists emphasize the importance of limited-duration use to balance efficacy with safety profile. Some reports indicate recurrence rates are lower with full-course treatment compared to early discontinuation.